Sai Life Sciences Soars: A Deep Dive into Q3 FY26 Performance and Strategic Vision

Sai Life Sciences Limited, a leading integrated Contract Research, Development, and Manufacturing Organization (CRDMO), has once again demonstrated robust financial and operational performance, significantly outpacing broader industry trends in the third quarter of fiscal year 2026. The company's latest investor presentation and earnings call for the period ending December 31, 2025, highlight strong growth across its core segments, driven by strategic investments in technology, capacity expansion, and a relentless focus on quality and customer partnerships.

The Hyderabad-headquartered firm reported an impressive 27% year-on-year increase in revenue from operations, reaching ₹556 crore for Q3 FY26. This growth was broad-based, with both its Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) services contributing significantly. The company's EBITDA surged by a remarkable 54% year-on-year to ₹191 crore, with EBITDA margins expanding by a substantial 605 basis points to 34%. Profit After Tax (PAT) witnessed an even more dramatic rise, climbing 86% year-on-year to ₹100 crore. For the nine-month period (9MFY26), the performance was equally stellar, with revenue up 43% to ₹1,590 crore, EBITDA up 79% to ₹472 crore, and PAT skyrocketing by 199% to ₹245 crore.

Segmental Prowess: CDMO and CRO Drive Growth

The company's integrated CRDMO model continues to be a key differentiator. In Q3 FY26, the CDMO segment contributed 65% of the total revenue, recording ₹361 crore, a 31% increase from Q3 FY25. This growth was primarily supported by sustained demand and healthy volume growth across key service lines. Management emphasized that a larger and more diversified pool of late-phase and commercial molecules has helped the business offset the impact of volume variability, which is often outside a CDMO's control. During the year, Sai Life Sciences added 7 molecules to its late-phase and commercial pipeline, bringing the total to 43 molecules, further broadening its portfolio and enhancing business resilience.

The CRO segment, comprising 35% of the revenue mix, also performed strongly, generating ₹195 crore in Q3 FY26, an increase of 19% from the previous year. The CRO business maintains strong growth momentum, supported by a clear focus on expanding engagements with large pharma customers. The company is actively strengthening its discovery engine through targeted investments in next-generation technologies, including AI-based retrosynthesis tools and advanced photochemical and electrochemical platforms. This focus on innovation helps deliver higher scientific value and shortens discovery timelines, making Sai Life Sciences an attractive partner for global innovators.

Financial Summary Table (₹ Crore)

Strategic Investments and Future Outlook

Sai Life Sciences is not just resting on its laurels; it is making significant strategic investments to fortify its foundation and build scale for future growth. The company has invested ₹405 crore in capital expenditure as of date, against a planned ₹700 crore for FY26. These investments are aligned with its long-term strategy to strengthen capabilities and expand capacity, ensuring future-ready infrastructure.

Key initiatives include a substantial manufacturing capacity expansion of approximately 450KL, with one production block of 225 KL expected to be commissioned by Q2 FY27 and a second block by the end of FY27. This expansion is projected to increase the company's manufacturing capacity by nearly 70%. Furthermore, a new CMC Process R&D Center is under construction at its Hyderabad campus, targeted for completion by September 2026. This facility will double Process R&D capacity and include specialized labs for peptides, amidites, and NCE formulation development.

In a notable corporate announcement on January 28, 2026, Sai Life Sciences disclosed a strategic collaboration with Mabtech to advance immunology research using the EYRA™ platform at its Boston site. This collaboration establishes Sai's Boston laboratory as a co-marketed US execution and demonstration hub for advanced immunology assay services, accelerating access to next-generation immune profiling capabilities for biopharma and biotech companies. This initiative underscores the company's commitment to innovation and strengthening its technology platforms.

The company is also making significant strides in AI and digital transformation, working on an end-to-end AI-driven pharma services business. An AI/ML model proof-of-concept outcome is expected in 2026, with the overall digitization process anticipated to be complete by 2027. These efforts are aimed at accelerating route design, improving synthetic efficiency, and enabling scientists to focus on high-value science. Sai Life Sciences is also expanding its capabilities in new modalities like Peptides, ADCs, Oligos, and TPDs, with dedicated process development and pilot facilities for these areas coming online by September and October 2026, respectively. The Phase I Animal Health expansion is also targeted for completion by March 2027, further diversifying its portfolio.

Management Commentary and Outlook

Mr. Krishna Kanumuri, Managing Director & CEO, highlighted the continued progress in building Sai Life Sciences into a science-led, globally relevant CRDMO. He emphasized strengthening technology platforms through greater adoption of digital, AI-enabled, and modern chemistry approaches. Mr. Siva Chittor, Chief Financial Officer, reiterated the robust growth and improved operating performance, driven by disciplined execution and healthy momentum. He noted that the company is on course to achieving its stated goal of 28-30% EBITDA margins ahead of schedule and expects to sustain this range.

Management acknowledged the inherent challenges of the CDMO business, such as volume variability and the unpredictability of destocking events. However, they are confident in mitigating these risks through a diversified portfolio and strong, long-standing customer relationships built over years of trust. The company's strategic focus on prudent capital allocation, margin discipline, and selective investments in differentiated value propositions positions it for another year of strong and profitable growth, creating enduring value for all stakeholders.

In conclusion, Sai Life Sciences Limited's Q3 FY26 performance reflects a company in strong growth trajectory, underpinned by strategic foresight, disciplined execution, and a clear vision for innovation. With significant investments in capacity, technology, and new modalities, coupled with robust financial health, the company appears well-positioned to capitalize on the expanding global CRDMO market and India's rising prominence as a strategic outsourcing hub.